Results 91 to 100 of about 1,044,683 (223)

Engineering metal‐organic framework‐based smart porous nanoplatforms for targeted therapy and theranostic applications

Smart Molecules, EarlyView.
MOFs offer high porosity and tunability for biomedical applications, especially in cancer therapy via ROS generation and targeted delivery. Though toxicity, stability, and scalability remain key clinical challenges. Drug loading in MOFs exceeds 60%–70% with controlled release behavior.
Jagabandhu Bag, Subhasis Banerjee, Sabyasachi Banerjee, Sourav De, S. K. Ashok Kumar, Yan‐Jye Shyong, Subhankar Mukhopadhyay   +6 more
wiley   +1 more source

Bilateral Facial Nerve Palsy After Weekly Nanoparticle Albumin–Bound Paclitaxel Treatment in Pancreatic Cancer

Annals of Internal Medicine: Clinical Cases
Peripheral neuropathy is a common side effect of microtubule inhibitors. Rare cases of cranial nerve palsies have been reported with paclitaxel and 1 case of unilateral facial nerve palsy has been reported with nanoparticle albumin-bound paclitaxel (nab ...
Vishal Yalamanchili, Ronald Harris
doaj   +1 more source

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors [PDF]

, 2007
Albumin-bound paclitaxel, ABI-007 (Abraxane ®), has a different toxicity profile than solvent-based paclitaxel, including a lower rate of severe neutropenia.
Collichio, Frances A., Ivanova, Anastasia, Hawkins, Michael J., Lindley, Celeste, O'Neil, Bert H., Stinchcombe, Thomas E., Walko, Christine M., Mu, Hua, Socinski, Mark A., Goldberg, Richard M., Claire Dees, E.   +10 more
core   +1 more source

Angiogenesis‐associated immune genes as prognostic markers and predictors of immunotherapy response in pancreatic ductal adenocarcinoma

VIEW, EarlyView.
Pancreatic ductal adenocarcinoma exhibits marked angiogenic and immune heterogeneity. We identified 28 angiogenesis‐associated immune genes and developed a seven‐gene AIGScore model comprising FGF2, ADGRB3, MMP2, TYMP, VASH1, VEGFD, and ITGAV. A high AIGScore was associated with poor survival, an immunosuppressive tumor microenvironment, and reduced ...
Qing Chang, Qian Wang, Xiumei Jiang, Yongmei Yang, Ailin Qu   +4 more
wiley   +1 more source

Nanoparticle Albumin-Bound Paclitaxel- and/or Gemcitabine-Induced Scleroderma Accompanied by Acanthosis Nigricans-Like Skin Changes

Case Reports in Dermatology, 2019
We herein present the first case of nanoparticle albumin-bound paclitaxel (nab-paclitaxel)- and/or gemcitabine-induced scleroderma accompanied by acanthosis nigricans-like skin changes in a 54-year-old Japanese male.
Sei-ichiro Motegi, Mai Ishikawa, Akiko Sekiguchi, Osamu Ishikawa   +3 more
doaj   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source

Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel

Small Science
Nab‐paclitaxel (Abraxane), an albumin‐bound solvent‐free paclitaxel (PTX) formulation that takes advantage of the endogenous albumin transport pathway, is the current gold standard for treatment of solid tumors with PTX.
Soumen Saha, Samagya Banskota, Parisa Yousefpour, Jeffrey L. Schaal, Nikita Zakharov, Jianqiao Liu, Michael Dzuricky, Ziwei He, Stefan Roberts, Xinghai Li, Ashutosh Chilkoti   +10 more
doaj   +1 more source

Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC).

, 2015
Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin bound (nab)-paclitaxel for newly diagnosed breast cancer (BC)
Anne Maree Woollett (13622302), Ian Collins (13064952), Susan Bowles (5279852), David M Ashley (11461396), Sujata Patil (674937), Conrad Brandt (13622290), Theresa M Hayes (13622311), Sally E Baron-Hay (13622299), Mustafa Khasraw (6335354), Shu Fen Wong (13622320), Violet Rudo Mukaro (13622284), Linda West (6335345), Michelle Edwards (343232), Alexander David Guminski (13622314), Gregory Mitchell (836801), Inger Helen Olesen (13668931), Kimberley Prince (13622308), Jacinta Bryan (13622317), Robert Spokes (13622305)   +18 more
core  

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Albumin-bound paclitaxel in the treatment of metastatic breast cancer

Modern Oncology, 2017
Metastatic breast cancer (mBC) continues to be an incurable disease, but modern drug therapy, associated with the steady extension of the arsenal of active cytostatic drugs and the development of new treatment options, provides the long-term control of tumor growth, transforming into chronic pathology.
openaire   +1 more source